Impact BioMedical Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Impact BioMedical Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IBO
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001834105
- EIN
- 85-3926944
Board of directors
-
Castel Berisford Hibbert · DirectorSince 2024
-
Christian Thomas Zimmerman · DirectorSince 2024
-
David K. Keene · DirectorSince 2024
-
Elise Brownell · DirectorSince 2024
-
Frank D. Heuszel · Director · Chief Executive OfficerSince 2024
-
Heng Fai Ambrose Chan · DirectorSince 2025
-
Jason Grady · DirectorSince 2024
-
Melissa Kaye Sims · DirectorSince 2024
Chief executives
Frank D. Heuszel
· CEO and President
Since September 2024
Director election results
Annual meeting of November 5, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.8%
-
99.9%
-
99.9%
-
99.9%
-
99.9%
-
99.9%
-
99.9%
Board connections
2 of this board's directors also sit on 3 other boards.
- via Frank D. Heuszel and Heng Fai Ambrose Chan
- via Heng Fai Ambrose Chan
- via Heng Fai Ambrose Chan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $59,450
- 6 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | DSS, INC. 10% owner | Open-market sale | −156 | $7.06 | $1,101 |
| Sep 23, 2026 | DSS, INC. 10% owner | Open-market sale | −27 | $6.95 | $188 |
| Sep 22, 2026 | DSS, INC. 10% owner | Open-market sale | −723 | $0.55 | $398 |
| Mar 27, 2026 | Macko Todd D Officer (Chief Financial Officer) | Open-market sale | −43,400 | $0.56 | $24,304 |
| Mar 25, 2026 | Macko Todd D Officer (Chief Financial Officer) | Open-market sale | −1,600 | $0.60 | $960 |
| Mar 23, 2026 | Jason Grady Director | Open-market sale | −50,000 | $0.65 | $32,500 |
| May 27, 2025 | DSS, INC. 10% owner | Open-market sale | −45,400 | $0.54 | $24,516 |
| May 27, 2025 | DSS, INC. 10% owner | Open-market sale | −45,400 | $0.54 | $24,516 |
| May 22, 2025 | DSS, INC. 10% owner | Open-market sale | −115,600 | $0.55 | $63,580 |
| May 22, 2025 | DSS, INC. 10% owner | Open-market sale | −115,600 | $0.55 | $63,580 |
| Apr 4, 2025 | DSS, INC. 10% owner | Open-market sale | −890,800 | $0.95 | $846,260 |
| Apr 4, 2025 | Heng Fai Ambrose Chan Director, 10% owner | Open-market sale | −180,000 | $0.96 | $172,800 |
| Apr 3, 2025 | Heng Fai Ambrose Chan Director | Open-market sale | −351,555 | $0.50 | $175,778 |
| Apr 3, 2025 | Heng Fai Ambrose Chan Director, 10% owner | Open-market sale | −351,631 | $0.58 | $203,946 |
| Apr 3, 2025 | Heng Fai Ambrose Chan Director, 10% owner | Open-market sale | −273,286 | $0.78 | $213,163 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.